GLP-1 and Multi-Agonist Peptides: Semaglutide to Retatrutide
No peptide family has drawn more scientific and public attention this decade than the incretin class – GLP-1 receptor agonists and their multi-receptor successors. This is a research-oriented map of the class: what each molecule is, how they differ structurally, and where each stands in development.
The biology in one paragraph
GLP-1 (glucagon-like peptide-1) is a gut hormone released after eating. It potentiates glucose-dependent insulin secretion, slows gastric emptying, and acts on appetite circuits in the brain. Native GLP-1 survives only minutes in circulation – the enzyme DPP-4 clips it almost immediately – so the entire drug class is an exercise in engineering peptides that keep the receptor activity while resisting degradation.
The molecules
Semaglutide is a GLP-1 analogue with two key modifications: an unnatural amino acid (Aib) at the DPP-4 cleavage position, and a C18 fatty-diacid chain that binds albumin and stretches the half-life to about a week. It is the active ingredient of approved pharmaceuticals (Ozempic, Wegovy, Rybelsus) – a completed development story.
Tirzepatide is a 39-residue single peptide engineered to activate two receptors: GIP (the other incretin) and GLP-1. Also an approved pharmaceutical ingredient (Mounjaro, Zepbound). The dual agonism concept – one chain, two receptor pharmacologies – is itself a significant piece of peptide engineering.
Retatrutide goes one further: a triple agonist at GIP, GLP-1, and glucagon receptors, currently investigational in late-stage clinical trials. The glucagon component adds an energy-expenditure dimension to the incretin effects, which is why it is among the most-watched molecules in metabolic research.
Cagrilintide comes from a different hormone family entirely – it is a long-acting amylin analogue, being studied in combination with semaglutide (the investigational pairing known as CagriSema). Amylin is co-secreted with insulin and acts on satiation signalling by its own receptor pathway.
Why research-grade versions exist
Laboratories study these peptides in receptor-pharmacology assays, cell models, and animal work – receptor selectivity, signalling bias, degradation kinetics, formulation behaviour. Research-grade semaglutide or retatrutide is not the pharmaceutical product: it is the peptide itself, supplied lyophilized for in-vitro work, with identity and purity documented per lot. That distinction matters legally and scientifically, and it is why everything in this class at VitaPep – semaglutide, tirzepatide, retatrutide, and cagrilintide – is sold strictly for laboratory research with a lot-specific certificate of analysis.
Handling notes
These are comparatively large, engineered peptides; the fatty-acylated members in particular are prone to aggregation if shaken during reconstitution. Swirl gently, refrigerate, and plan concentrations with the calculator.
All compounds supplied by VitaPep are for in-vitro laboratory research use only. Nothing on this page is guidance for human or veterinary use of any kind.
EDUCATIONAL CONTENT ON PUBLISHED RESEARCH · ALL VITAPEP PRODUCTS ARE FOR LABORATORY RESEARCH USE ONLY AND NOT FOR HUMAN OR VETERINARY USE.